2021 BQ Journal Vol 42 - 38

Impact of SARS-CoV-2 Infection during Pregnancy on Obstetric and Neonatal
Outcomes - Icahn School of Medicine at Mt. Sinai
The Icahn School of Medicine at Mt. Sinai is conducting a study to determine SARS-CoV-2 sero-prevalence among pregnant
women, that is, the estimated percentage of pregnant women who have been infected with SARS-CoV-2, the virus that causes
COVID-19. Using data from electronic health records, the study also examines associations between SARS-CoV-2 infection and
adverse pregnancy outcomes. Researchers will determine the extent to which SARS-CoV-2 infection impacts pregnant women
in underserved communities in New York City and will explore the role of maternal stress.

Perinatal COVID-19 in the U.S.: Surveillance and Epidemiology - Children's
Hospital of Philadelphia (CHOP) and the University of Florida, College of
Medicine - Jacksonville
This national registry at Children's Hospital of Philadelphia (CHOP) and the University of Florida, College of Medicine -
Jacksonville is measuring the current burden of SARS-CoV-2 infection during pregnancy to inform clinical care practices and
provide data for future studies on prevention, diagnosis, and treatment of COVID-19. The study is using a robust, real-time
national registry to capture information about pregnant women with COVID-19 and their newborn infants. The information
collected will contribute to a greater understanding of the potential modes of transmission, risk factors, and rates of
transmission of SARS-CoV-2 infection during pregnancy and the impact on the newborn.

Pregnancy and Household Transmission COVID-19 Study - University of Washington
The University of Washington is conducting a study in South King County, Washington on SARS-CoV-2 prevalence, household
transmission, and antibody response among pregnant women and their household members. The study is investigating
adverse health outcomes and other factors associated with symptomatic and asymptomatic SARS-CoV-2 infection among 1,000
pregnant women screened for SARS-CoV-2 specific IgG antibodies. It is also estimating potential household transmission and
duration of antibodies over time (6 months) among pregnant women and their household contacts.

Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network
The ESPI Electronic Cohort study is collecting information from the medical records of women who receive prenatal care at three
participating sites and reach the end of their pregnancy between March 2020 and February 2021. Data collection will include
information about the following:
*
*
*
*

Demographic and maternal characteristics
Medical conditions
Prenatal care
Pregnancy complications, including ambulatory care visits and
hospitalizations for acute illness

*
*
*
*

Postpartum care
Laboratory test results for SARS-CoV-2 and influenza
Pregnancy outcomes
Selected infant outcomes through 6 months of age

This study aims to understand the characteristics of SARS-CoV-2 infection during pregnancy and the six months after the end
of pregnancy, including among infants up to six months of age. It also aims to identify risk factors for severe COVID-19 disease,
describe use of investigational and off-label therapeutics, and evaluate effects of COVID-19 on pregnancy and infant outcomes.
The ESPI Community Cohort study is a multisite collaboration designed to estimate the incidence of asymptomatic and
symptomatic SARS-CoV-2 infection and understand the characteristics of SARS-CoV-2 infection in pregnant women. This includes
the spectrum of disease, conditions, and risk factors for infection and developing severe illness. As a secondary objective, this
study will examine the effect of COVID-19 during pregnancy on pregnancy and newborn outcomes. The study enrolls pregnant
women at less than 28 weeks of pregnancy and follows them through the end of their pregnancies with weekly surveillance for
SARS-CoV-2 infection and symptoms of COVID-19-like illness. Information is also collected two to four weeks after the end of
their pregnancies, on end-of-pregnancy, infant, and postpartum outcomes.

cdc.gov/coronavirus
Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News
A Henry Schein Publication

38
http://www.cdc.gov/coronavirus
2021 BQ Journal Vol 42

Table of Contents for the Digital Edition of 2021 BQ Journal Vol 42
